ESMO 2021 | Current standards for first-line metastatic hormone-sensitive prostate cancer

Paul Monk, MD, Ohio State University Comprehensive Cancer Center, Columbus, OH, discusses the treatments for patients with castration-resistant prostate cancer. These patients are resistant to androgen receptor targeting drugs and are therefore usually treated with enzalutamide and abiraterone. Nevertheless, alternative more efficacious treatments are needed. Dr Monk explains that the results from the Phase Ib/II trial (NCT03910660) evaluating BXCL701 (talabostat) in combination with pembrolizumab are eagerly awaited to see if this new agent demonstrates a significant efficacy and acceptable toxicity profile in this patient population.